Source:http://linkedlifedata.com/resource/pubmed/id/10796556
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2000-7-6
|
| pubmed:abstractText |
To assess the efficacy, dose-responsiveness and safety of the newer release formulations of 5-aminosalicylic acid (5-ASA) compared to placebo or sulfasalazine (SASP) in the maintenance of remission in ulcerative colitis.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1469-493X
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
CD000544
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
2000
|
| pubmed:articleTitle |
Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis.
|
| pubmed:affiliation |
Division of Gastroenterology, University of Calgary, Foothills Hospital, 1751 3330 Hospital Drive N W, CALGARY, AB, Canada, T2N 4N1. lsutherl@acs.ucalgary.ca
|
| pubmed:publicationType |
Journal Article,
Review
|